Core Insights - The company reported a revenue of 676 million yuan (approximately 94.37 million USD) for the first half of 2025, a decrease of 6.9% compared to the same period last year [2] - The net loss for the first half of 2025 was 67.95 million yuan, compared to a net loss of 60,000 yuan in the same period last year [2] Q2 Financial Performance - The revenue for Q2 2025 was 379 million yuan (approximately 52.90 million USD), down 7% from 407 million yuan in the same quarter last year [5] - Medical aesthetic treatment service revenue in Q2 2025 was 144.4 million yuan (approximately 20.20 million USD), an increase of 426% from 27.4 million yuan year-over-year, driven by the expansion of brand medical aesthetic centers [5] - Information and appointment service revenue for Q2 2025 was 135.2 million yuan (approximately 18.90 million USD), a decrease of 35.6% from 209.7 million yuan year-over-year, primarily due to a reduction in the number of medical service providers subscribing to information services on the platform [5] - Sales of medical products and maintenance services in Q2 2025 were 76 million yuan (approximately 10.60 million USD), down 28.1% from 105.8 million yuan year-over-year, mainly due to a decline in medical product order volume [5] - Other service revenue in Q2 2025 was 23.2 million yuan (approximately 3.20 million USD), a decrease of 64.0% from 64.4 million yuan year-over-year, attributed to a reduction in premium service revenue [5] Profitability and Costs - Gross profit for Q2 2025 was 194 million yuan, with a gross margin of 51% [8] - Total expenses for Q2 2025 were 241.3 million yuan (approximately 33.70 million USD), a decrease of 1.8% from 245.6 million yuan year-over-year [11] - Sales and marketing expenses in Q2 2025 were 131.3 million yuan (approximately 18.30 million USD), down 0.7% from 132.3 million yuan year-over-year, mainly due to a reduction in wage costs [11] - General and administrative expenses were 78.8 million yuan, an increase of 11.3% from 70.8 million yuan year-over-year, driven by an increase in administrative staff to support business upgrades and new strategic initiatives [11] - R&D expenses were 31.2 million yuan, down 26.6% from 42.5 million yuan year-over-year, attributed to improved employee efficiency [11] Losses and Cash Position - Operating loss for Q2 2025 was 47.11 million yuan, compared to an operating profit of 6.72 million yuan in the same quarter last year, resulting in an operating margin of -12% [13] - The net loss for Q2 2025 was 34.80 million yuan, compared to a net profit of 20.12 million yuan in the same period last year [16] - As of June 30, 2025, the company held cash and cash equivalents, restricted cash, and short-term investments totaling 998.6 million yuan (approximately 139.4 million USD), down from 1.2532 billion yuan at the end of 2024 [17] Future Outlook - The company expects Q3 2025 revenue from beauty treatment services to be between 150 million yuan (approximately 20.90 million USD) and 170 million yuan (approximately 23.70 million USD), representing a year-over-year growth of 230.5% to 274.6% [17] - The company's stock price closed at 3.74 USD, down 22.73% from the previous day, with a market capitalization of 375 million USD [17]

Group 1 - The core viewpoint of the article highlights that New Oxygen Technology (SY.US) reported a revenue decline in Q1 2025, but still exceeded market expectations [1] - In Q1 2025, the company's revenue reached 40.97 million USD, a decrease of 6.6% year-on-year, while the GAAP diluted loss per share was 0.04 USD, slightly better than the market average expectation of a loss of 0.05 USD [1] - The decline in revenue was primarily due to a reduction in the number of medical beauty institutions on the subscription platform [1] Group 2 - The total transaction amount for medical beauty treatments facilitated by the platform in Q1 was 30.32 million RMB, down from 36.71 million RMB in the same period of 2024 [1] - The number of verified paid visits exceeded 45,500, showing a nearly ninefold increase compared to approximately 4,600 visits in the same period of 2024 [1] - The number of active users as of March 31, 2025, was over 75,700, compared to about 8,000 in the same period of 2024 [1] Group 3 - As of March 31, 2025, New Oxygen operates 23 medical beauty centers in nine major cities, with 18 centers achieving positive monthly operating cash flow [2] - For Q2 2025, the company expects medical beauty service revenue to be between 120 million RMB (approximately 16.5 million USD) and 140 million RMB (approximately 19.3 million USD), representing a year-on-year growth of 337.3% to 410.1% compared to the same period in 2024 [2]

Financial Data and Key Metrics Changes - In Q4 2024, total revenue was RMB 369.2 million, a decrease of 5.5% year-over-year, primarily due to a decline in revenue from So-Young Prime [23] - Net loss attributable to So-Young was RMB 607.6 million, compared to a net income of RMB 17.5 million in the same period last year [27] - Non-GAAP net loss was RMB 53.2 million, compared to a non-GAAP net income of RMB 35.7 million in the same period of 2023 [27] - For the full year 2024, total revenues were RMB 1.47 billion, down 2.1% year-over-year [28] Business Line Data and Key Metrics Changes - Revenue from aesthetic treatment services surged to RMB 81.3 million in Q4, up 701.6% year-over-year, driven by the expansion of the aesthetic center business [23] - Sales of medical products and maintenance services were RMB 86.2 million, down 15.2% year-over-year, primarily due to a decrease in order volume for medical equipment [23] - Total operating expenses were RMB 815.2 million, up 216.2% year-over-year, with significant increases in sales and marketing expenses [25] Market Data and Key Metrics Changes - The total number of verified paid aesthetic treatments surpassed 81,500, with over 38,000 verified paid visits recorded [10] - The aesthetic center network demonstrated strong growth, with 19 clinics opened across nine core cities, and 11 centers achieving positive monthly operating cash flow in December [9] Company Strategy and Development Direction - The company is focused on vertical integration within the aesthetic medical industry, leveraging its user base and supply chain capabilities to drive growth [7][32] - The aesthetic center business is seen as a new growth engine, with plans to replicate successful models across more locations [14] - The company aims to establish a leading position in the market by expanding its aesthetic center network, which currently has a low penetration rate in China [51][52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the aesthetic center network, citing the low market share of chain clinics in China [51] - The company anticipates steady improvement in financial performance as market conditions stabilize and the aesthetic center business continues to expand [32] - Management highlighted the importance of maintaining a balance between growth and profitability while enhancing financial resilience [67] Other Important Information - The company recorded a one-time goodwill impairment charge of RMB 540 million for its subsidiary, impacting the bottom line [7] - Cash and cash equivalents, along with term deposits and short-term investments, totaled RMB 1.25 billion as of December 31, 2024, indicating a robust cash position [30] Q&A Session Summary Question: What are the latest developments in merchant support during the industry consolidation period? - Management noted that as industry consolidation accelerates, large chain institutions are gaining market share, and So-Young is optimizing its platform to empower aesthetic institutions and improve user experience [36][37] Question: How does the company adapt its strategies for centers at different stages of development? - Management explained that differentiated operational strategies are implemented at various phases to ensure optimal performance and enhance brand influence [44][46] Question: Can the aesthetic center business maintain growth? - Management affirmed that the aesthetic center network has the capability for sustained growth, citing the low penetration rate of chain clinics in China as an opportunity for expansion [51][52] Question: What is the strategy for the upstream business? - Management discussed the integration of Miracle Laser into So-Young's upstream business, focusing on product innovation and enhancing collaboration to drive sustainable growth [58][60] Question: Could management share more insights into the company's financial outlook? - Management emphasized a commitment to sustainable growth through vertical integration, balancing growth with profitability, and maintaining financial resilience [67]